ITMCTR2000003269RecruitingPhase 1
Study on treatment of traditional Chinese medicine of anti-tuberculosis drug-induced liver injury
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine0 sitesStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional study
Eligibility Criteria
- Ages
- 18 to 75 (—)
- Sex
- All
Inclusion Criteria
- •1. Those who meet the diagnostic criteria for tuberculosis and have abnormal liver function after applying anti-tuberculosis drugs;
- •2. The severity of DILI is graded 1-2;
- •3. The age range is between 18-75 years old;
- •4. Not taking other drugs to protect liver and reduce enzyme, Or has been suspended for more than 2 weeks;
- •5. Signed informed consent voluntarily.
Exclusion Criteria
- •1. The liver function test before medication is elevated in alanine aminotransferase or bilirubin, and any of them is> 2 times the upper limit of normal value;
- •2. People with HIV infection, the original history of viral hepatitis or serological signs of hepatitis Those with positive substance;
- •3. Combined with serious primary diseases such as cardiocerebrovascular, kidney, hematopoietic system, peptic ulcer, or serious diseases (such as tumors) that affect their survival, or patients with mental or legal disabilities;
- •4. Do have a history of alcohol and drug abuse;
- •5. Allergic constitution, or known to be allergic to the drug components in the test protocol;
- •6. Pregnant, pregnant or lactating women.
Investigators
Similar Trials
Recruiting
Phase 1
Clinical study of the traditional Chinese medicine wenyangtongluo formula combined with toripalimab plus apatinib and tegio as the third line for advanced gastric cancerStomach cancerITMCTR2200005508Department of Oncology of Integrated Traditional Chinese and Western Medicine, High-tech Campus, First Affiliated Hospital of Anhui
Not yet recruiting
Not Applicable
A clinical study of traditional Chinese medicine combined with western medicine in treatment of primary IgA nephropathy (IgAN) in CKD stage 3ITMCTR2200006488Shanghai east hospital (East Hospital affiliated to Tongji University)
Not yet recruiting
Phase 1
Analysis on the Distribution of TCM Syndromes in convalescent novel coronavirus pneumonia (COVID-19) patientsovel Coronavirus Pneumonia (COVID-19)ITMCTR2000003991Beijing University of Chinese Medicine Third Affiliated Hospital
Not yet recruiting
Phase 1
A Randomized Controlled Clinical Study for Traditional Chinese Medicine to Improve the Clinical Benefit Rate of Advanced Esophageal CancerM8000/3Esophageal cancerITMCTR2000003504Henan Province Hospital of TCM
Not yet recruiting
Phase 1
A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trailGastric CancerITMCTR1900002830Jiangsu Province Hospital of Chinese Medicine